Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02615938Phase 2Terminated

Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)

Role: lead

NCT02631603Phase 2Terminated

Stop Exogenous Allergic Alveolitis (EAA) in Childhood

Role: lead

NCT02852928Recruiting

European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

Role: lead

All 3 trials loaded